Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2018-11-16 Earnings Release
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Third Quarter Financial Report
Earnings Release Classification · 99% confidence The document explicitly states it contains "Third quarter 2018 results" and provides detailed financial performance metrics for 3Q18 compared to 3Q17, including Sales and Geographic Split, Cost of Goods Sold, Operating Expenses, Earnings (EBITDA, Net Profit), Balance Sheet data as of 30.09.2018, and Cash Flow statements for the period. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year. The presence of detailed financial tables and comparative figures strongly points towards an Interim/Quarterly Report, which corresponds to the 'IR' code. It is not an Earnings Release (ER) because it is comprehensive, not just highlights, and it is not a 10-K as it covers only the third quarter. Q3 2018
2018-11-16 English
Third Quarter Financial Report
Report Publication Announcement Classification · 95% confidence The document is a short announcement (921 characters) that summarizes key highlights of the third quarter results and explicitly states 'Please find the report enclosed', indicating that the actual financial report is a separate attachment. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). Q3 2018
2018-11-16 English
Gentian Diagnostics AS - Primary insider notification
Director's Dealing Classification · 99% confidence The document is titled 'Gentian Diagnostics AS - Primary insider notification' and details a share acquisition by Vatne Equity AS, where an associated individual (Henrik Krefting) is a Board Member of Gentian Diagnostics AS. This clearly indicates a report of personal share transactions by company directors or executives (insider trades). This aligns directly with the definition for Director's Dealing (DIRS). The document length is short (1113 chars), but the content is the transaction itself, not an announcement of a report, so DIRS is the correct classification over RPA/RNS.
2018-10-03 English
Results from Calprotectin study
Environmental & Social Information Classification · 99% confidence The document text is a scientific paper or abstract detailing a medical study on biomarkers (Calprotectin, HBP, Procalcitonin) for diagnosing sepsis and predicting mortality in ICU patients. It includes an Introduction, Results, Conclusion, Methods, author affiliations, and a data table. This content does not align with standard financial filings like 10-K, ER, IR, or AGM materials. It most closely resembles a research article or a specialized report. Given the provided classification options, none perfectly fit a medical research paper. However, since it is a detailed report containing extensive data and analysis, and it is not a regulatory filing, earnings release, or standard corporate report, the closest general category for non-standard, detailed reports that might be shared with investors or regulators in a specialized context, or simply as a fallback for non-financial documents, is 'Regulatory Filings' (RNS) or perhaps 'Audit Report / Information' (AR) if interpreted very broadly as a 'report'. Since it is clearly a scientific/medical report and not a financial filing, and RNS is the general fallback for miscellaneous filings, I will use RNS as the best fit among the limited financial categories, acknowledging the mismatch. If 'Research Report' were an option, that would be ideal. Given the strict list, RNS is the most appropriate fallback for a document that is clearly not one of the primary financial types.
2018-10-01 English
Results from Calprotectin study
Report Publication Announcement Classification · 98% confidence The document is a short announcement (2533 characters) from Gentian Diagnostics AS regarding the publication of results from a study comparing the biomarker calprotectin with PCT and HBP in sepsis patients. The text explicitly states that the results were 'published at the International Sepsis Forum' and concludes with 'Please see the enclosed research poster for further information.' This structure—a brief announcement about the release/publication of external material (a study/poster)—fits the definition of a Report Publication Announcement (RPA). It is not the full study itself, nor is it a standard regulatory filing like 10-K, ER, or IR.
2018-10-01 English
Patent licensing agreement
Regulatory Filings Classification · 95% confidence The document announces that a subsidiary has entered into a patent licensing agreement, receiving a lump sum payment. This transaction involves a change in asset utilization and a one-time revenue recognition event. It is not a standard periodic financial report (10-K, IR, ER), a management change (MANG), or a standard dividend announcement (DIV). It relates to a specific corporate transaction that impacts the company's structure/assets, but it is not a merger/takeover (TAR). Since it is a specific, material corporate event announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a catch-all for significant, non-standard announcements not covered elsewhere. Given the short length and announcement nature, RNS is the most appropriate fit among the provided options.
2018-09-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.